BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 32152523)

  • 1. Programmed axon degeneration: from mouse to mechanism to medicine.
    Coleman MP; Höke A
    Nat Rev Neurosci; 2020 Apr; 21(4):183-196. PubMed ID: 32152523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.
    Loreto A; Hill CS; Hewitt VL; Orsomando G; Angeletti C; Gilley J; Lucci C; Sanchez-Martinez A; Whitworth AJ; Conforti L; Dajas-Bailador F; Coleman MP
    Neurobiol Dis; 2020 Feb; 134():104678. PubMed ID: 31740269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.
    Gerdts J; Summers DW; Milbrandt J; DiAntonio A
    Neuron; 2016 Feb; 89(3):449-60. PubMed ID: 26844829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarm1 Deletion, but Not Wld
    Gilley J; Ribchester RR; Coleman MP
    Cell Rep; 2017 Oct; 21(1):10-16. PubMed ID: 28978465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wallerian degeneration: an emerging axon death pathway linking injury and disease.
    Conforti L; Gilley J; Coleman MP
    Nat Rev Neurosci; 2014 Jun; 15(6):394-409. PubMed ID: 24840802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chemical biology of NAD
    Icso JD; Thompson PR
    Curr Opin Chem Biol; 2022 Aug; 69():102176. PubMed ID: 35780654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARM1 can be a potential therapeutic target for spinal cord injury.
    Lu Q; Botchway BOA; Zhang Y; Jin T; Liu X
    Cell Mol Life Sci; 2022 Feb; 79(3):161. PubMed ID: 35224705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
    Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
    Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2.
    Walker LJ; Summers DW; Sasaki Y; Brace EJ; Milbrandt J; DiAntonio A
    Elife; 2017 Jan; 6():. PubMed ID: 28095293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.
    White MA; Lin Z; Kim E; Henstridge CM; Pena Altamira E; Hunt CK; Burchill E; Callaghan I; Loreto A; Brown-Wright H; Mead R; Simmons C; Cash D; Coleman MP; Sreedharan J
    Acta Neuropathol Commun; 2019 Oct; 7(1):166. PubMed ID: 31661035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.
    Loring HS; Thompson PR
    Cell Chem Biol; 2020 Jan; 27(1):1-13. PubMed ID: 31761689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial dysfunction as a trigger of programmed axon death.
    Merlini E; Coleman MP; Loreto A
    Trends Neurosci; 2022 Jan; 45(1):53-63. PubMed ID: 34852932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration.
    Gould SA; Gilley J; Ling K; Jafar-Nejad P; Rigo F; Coleman M
    Cell Rep; 2021 Dec; 37(11):110108. PubMed ID: 34910914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SARM1 axon degeneration pathway: control of the NAD
    Figley MD; DiAntonio A
    Curr Opin Neurobiol; 2020 Aug; 63():59-66. PubMed ID: 32311648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.
    Alexandris AS; Ryu J; Rajbhandari L; Harlan R; McKenney J; Wang Y; Aja S; Graham D; Venkatesan A; Koliatsos VE
    Neurobiol Dis; 2022 Sep; 171():105808. PubMed ID: 35779777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly.
    Neukomm LJ; Burdett TC; Seeds AM; Hampel S; Coutinho-Budd JC; Farley JE; Wong J; Karadeniz YB; Osterloh JM; Sheehan AE; Freeman MR
    Neuron; 2017 Jul; 95(1):78-91.e5. PubMed ID: 28683272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo.
    Di Stefano M; Loreto A; Orsomando G; Mori V; Zamporlini F; Hulse RP; Webster J; Donaldson LF; Gering M; Raffaelli N; Coleman MP; Gilley J; Conforti L
    Curr Biol; 2017 Mar; 27(6):784-794. PubMed ID: 28262487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
    Garb J; Amitai G; Lu A; Ofir G; Brandis A; Mehlman T; Kranzusch PJ; Sorek R
    PLoS One; 2024; 19(4):e0302251. PubMed ID: 38635746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria.
    Kitay BM; McCormack R; Wang Y; Tsoulfas P; Zhai RG
    Hum Mol Genet; 2013 Apr; 22(8):1601-14. PubMed ID: 23314018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
    Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
    JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.